Aine Miller - 19 May 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
SVP, DEV & HEAD OF IRE OFFICE
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
19 May 2025
Net transactions value
-$91,674
Form type
4
Filing time
21 May 2025, 19:22:01 UTC
Previous filing
04 Mar 2025
Next filing
22 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Miller Aine SVP, DEV & HEAD OF IRE OFFICE C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO /s/ Brett A. Grimaud, Attorney-in-Fact 21 May 2025 0002012524

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $0 +10,430 +4.9% $0.000000 224,691 19 May 2025 Direct F1
transaction TBPH Ordinary Shares Tax liability $91,674 -9,701 -4.3% $9.45 214,990 20 May 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 2, 2024 the reporting person was granted a performance restricted stock unit award that vests based on the achievement of certain performance conditions and continued employment. On May 19, 2025, the performance conditions were deemed achieved as to 10,430 RSUs, and such RSUs are eligible to vest based on the reporting person's continued service.
F2 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.